In regards to the stock of this high-quality pharmaceutical distributor, the author of today’s article declares that it “is not just cheap – it’s incredibly cheap.” But what about concerns the market currently has about this stock – namely Amazon’s entrance into the drug distribution space and White House rhetoric on drug prices? The author lays out how, under even the worst-case scenario for this company, it’s a “heads we win, tails we get less, but we still win” scenario for investors. For more, CLICK HERE.
When it comes to identifying stocks that you can buy and hold for years, the author of today’s article points to three important criteria: attractive valuations, great (and growing) dividends, and solid long-term growth prospects. He proceeds to highlight three big pharma stocks that appear to meet all three criteria – and which therefore could be solid long-term bets. For these three stocks – and some of the promising drug candidates in their pipelines – CLICK HERE.
Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for it. As such, this once obscure disease has become a top area of focus for drug makers, and as today’s article notes, “NASH is also predicted to be the next huge market opportunity for the biopharmaceutical industry, with some forecasting a global market size of as much as $35 billion per year.” For investors looking to cash in on the NASH dash, the author highlights a number of biopharmaceutical stocks to consider. For more, CLICK HERE.
Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans exorbitant amounts for the drugs they require. However, new legislation recently signed into law – the 21st Century Cures Act – seeks to streamline the approval process and bring new drugs to market faster, which the author notes “could be a boon for Big Pharma.” So, how can investors profit from this boon? The author highlights two top players in the generic pharmaceutical sector – as well as a biotech ETF that “gives you exposure to potentially huge moves from the little guys” – to consider. To read more, CLICK HERE.